French biopharmaceutical company EVerZom has secured €3 million in government funding through the France 2030 plan to accelerate the industrialization of its exosome-based bioproduction platform. The funding, awarded through the "Biotherapies and Bioproduction of Innovative Therapies" call for projects and operated by Bpifrance, will enable the company to advance its proprietary drug candidates toward late-stage clinical development and commercialization.
Industrial Scale-Up for Clinical Production
The funding represents a critical milestone in EVerZom's industrial scale-up strategy. The company will use the investment to scale up its exosome bioproduction technology in 50L GMP bioreactors, achieving production levels compatible with late-stage clinical phases and market launch.
"The French government's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition," said Jeanne Volatron, CEO of EVerZom. "Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments."
Exosome Technology Platform
EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Exosomes are tiny biological vesicles measuring 30 to 150 nanometers that are naturally secreted by cells and play a key role in intercellular communication by transporting proteins, messenger RNAs, and other functional biomolecules between cells.
Compared to the cells themselves, exosomes offer numerous advantages including increased stability, reduced variability, enhanced patient safety, and simplified logistics with direct hospital storage and immediate availability.
EVerGel Shows Promise for Crohn's Disease
EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial to enable prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide.
Initial preclinical results demonstrate significant therapeutic potential. In a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group.
Based on these promising results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030.
Broader Therapeutic Applications
The potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens opportunities for applications beyond the initial indication. EVerZom has identified potential applications in neurodegenerative diseases, age-related disorders, and regenerative cosmetics. The company has established around twenty global partnerships with players in human health, animal health, and cosmetics sectors.
France 2030 Strategic Initiative
The €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology. The program aims to transform key sectors of the economy through technological innovation and position France as a leader in future technologies.
Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. The company maintains a proprietary technology for the production and purification of exosomes and focuses on addressing unmet medical needs in chronic inflammatory and degenerative diseases.
